Tissue engineering has brought revolutionary potential to the regenerative repair of damaged tissues, providing innovative solutions to restore function.

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite ...

Catalent, Inc., a leading global contract development and manufacturing organization, today highlighted new innovations from its SMARTag® antibody-drug conjugate (ADC) technology platform. The company ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...

Utrecht University, University Medical Center Utrecht, and Princess Máxima Center have each been awarded a Vidi grant worth up to €850,000.

The proposed dual listing on both NASDAQ and HKEX is a key element of our global growth strategy ... activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 ...

IND application filed for MP0712, the Company's lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images f ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, yet their efficacy varies widely across individuals. Emerging evidence ...